Can Famotidine Cause Dementia? Examining the Evidence

Famotidine, one of the most widely used over-the-counter heartburn drugs, has not been convincingly linked to dementia in the available research. The evidence is mixed and often misunderstood, partly because famotidine gets lumped in with other acid-suppressing drugs that carry their own baggage. What the science actually shows is a complicated picture: famotidine barely reaches the brain, large epidemiological studies have produced conflicting results, and a few animal studies even hint at neuroprotective effects. The concern is worth examining carefully, though, because millions of people take this drug regularly and cognitive decline is a legitimate worry as people age.

Why Famotidine Gets Caught Up in Dementia Concerns

Famotidine belongs to a class called H2 receptor antagonists, which reduce stomach acid by blocking histamine receptors in the gut lining. The dementia worry comes from a reasonable-sounding chain of logic: histamine receptors also exist in the brain, histamine plays a role in learning and memory, so blocking those receptors might impair cognition over time. Mice engineered to lack H2 receptor function in certain brain cells do show cognitive problems, including impaired working memory and disrupted neural signaling in the prefrontal cortex.¹ And when H2 receptor antagonists are applied directly to brain tissue in animal experiments, they can block histamine’s ability to strengthen memory consolidation.²

That all sounds alarming until you consider a critical detail: famotidine taken by mouth or even by injection does a poor job of actually getting into the brain. Unlike cimetidine, an older H2 blocker that crosses the blood-brain barrier more readily, famotidine penetrates this protective barrier poorly.³ This is a well-established pharmacological property that has been recognized since the drug’s early clinical use.⁴ So while the theoretical concern about blocking brain H2 receptors makes sense in a petri dish or when drugs are injected directly into the brain, the real-world question is whether enough famotidine actually reaches the brain to matter.

What the Population Studies Show

If famotidine truly caused dementia at the rates people worry about, you would expect large epidemiological studies to show a clear, consistent signal. They don’t. The Rotterdam Study, one of the earlier and more carefully designed investigations, compared H2 blocker users to non-users and found no meaningful difference in Alzheimer’s disease risk, with an adjusted odds ratio of 0.95, which is essentially no effect at all.⁵

A larger study following older adults over an average of nearly seven years also found no overall link between H2 blocker use and dementia. The one caveat: among people with the heaviest cumulative use, there was a modest suggestion of elevated Alzheimer’s risk, though the confidence intervals were wide enough that the finding was borderline at best.⁶ That kind of signal at the extreme end of use, disappearing in the main analysis, is exactly what you’d expect to see from confounding rather than a true drug effect. People who take the most acid-suppressing medication over the longest period tend to be sicker in general, and sicker people are at higher baseline risk for dementia.

Not all studies are so reassuring, though. A Taiwanese population-based study found that both H2 blockers and proton pump inhibitors were associated with higher dementia rates among people with upper gastrointestinal disease, with an adjusted hazard ratio of about 1.36 for H2 blockers.⁷ An Italian cohort study reported an even higher hazard ratio of 1.84 for H2 blocker users compared to non-users.⁸

How do you reconcile these contradictions? The studies showing higher risk tend to have the same limitations: they cannot fully control for the reasons people take acid suppressants in the first place. Chronic gastrointestinal disease, poor nutrition, polypharmacy, and the general frailty that leads to heavy medication use are all independently associated with cognitive decline. Observational studies can adjust for some of these factors, but they can never fully eliminate what researchers call confounding by indication. Put simply, the drug use might be a marker for ill health rather than a cause of dementia.

Delirium Is Not Dementia

One important source of confusion in public discussions is the conflation of delirium with dementia. Delirium is a sudden, temporary state of confusion that clears up when the triggering factor is removed. Dementia is a chronic, progressive decline in cognitive function. They are fundamentally different conditions, even though they can look similar at the bedside.

Famotidine has been linked to delirium in a small number of case reports. A case series described six hospitalized patients who developed delirium while on famotidine, all of whom recovered completely once the drug was stopped.⁹ Another report documented a 77-year-old man who developed confusion, disorientation, and nightmares after switching to famotidine from ranitidine; his symptoms went away within two days of stopping the drug, and returned when he tried it again.¹⁰ Two elderly patients with mild kidney problems developed reversible confusion after receiving famotidine intravenously, possibly because impaired kidney function allowed more of the drug to accumulate in the body and, potentially, cross into the brain.¹¹

These case reports are worth knowing about, but they describe a temporary and reversible phenomenon in specific vulnerable populations, not the slow, permanent neurodegeneration that characterizes dementia. The 2023 American Geriatrics Society Beers Criteria, which lists medications that may be inappropriate for older adults, does flag H2 receptor antagonists including famotidine as drugs to avoid in people who have or are at high risk for delirium. The strength of evidence for this recommendation is rated as low.¹² The Beers Criteria listing is about acute delirium risk, not long-term dementia risk, and the distinction matters a great deal.

Kidney Function Changes the Equation

A factor that often gets overlooked in public discussions is how kidney function affects famotidine’s behavior in the body. The drug is eliminated primarily through the kidneys. When kidney function is reduced, famotidine sticks around longer and reaches higher blood levels, which increases the chance of any side effect, including cognitive ones.

A study of patients with end-stage kidney disease found that the vast majority, 35 out of 38, showed no mental status changes while receiving famotidine. The three who did experience changes were on doses that may not have been adequately adjusted for their kidney function.¹³ This is a practical point: if you have significant kidney impairment and take famotidine, your doctor should adjust the dose. At proper doses, even people with severely compromised kidneys mostly tolerate it without cognitive effects.

The early case reports of famotidine-related confusion involved intravenous administration or patients with reduced kidney function, which are not typical scenarios for someone picking up a box of Pepcid at the pharmacy. A healthy adult with normal kidney function taking a standard over-the-counter dose is in a very different risk category from a hospitalized elderly patient receiving IV famotidine with failing kidneys.

How Famotidine Compares to Proton Pump Inhibitors

Much of the public anxiety about acid suppressants and dementia was originally driven by studies of proton pump inhibitors like omeprazole and esomeprazole, not H2 blockers like famotidine. PPIs work through an entirely different mechanism, suppressing acid more powerfully, and the concerns about them have been studied far more extensively. A systematic review and meta-analysis that specifically compared PPI users to H2 blocker users found essentially no difference in dementia risk between the two groups, with a relative risk of 1.03.¹⁴ That finding suggests that whatever signal exists in observational data likely reflects factors common to all acid suppressant users rather than something specific to either drug class.

The Taiwanese study mentioned earlier actually found a larger signal for PPIs than for H2 blockers, with adjusted hazard ratios of roughly 1.89 versus 1.36.⁷ The Italian study, by contrast, found the opposite pattern: a higher hazard ratio for H2 blockers than for PPIs.⁸ When different studies point in opposite directions about which drug class is riskier, and a head-to-head meta-analysis shows no difference, the most parsimonious explanation is that neither drug is actually driving the risk. Confounding factors that are common to people who need chronic acid suppression are the more likely culprit.

The Gut Microbiome Angle

A more recent line of research has explored whether acid-suppressing drugs might affect cognition indirectly, through the gut microbiome. An animal study tested famotidine, esomeprazole, and vonoprazan in rats subjected to chronic stress. All three drugs, when combined with stress, led to worse performance on memory tasks compared to stress alone. The researchers observed changes in the ratio of key gut bacterial populations, disruption of gut membrane integrity, increased systemic inflammation, and elevated levels of amyloid-beta and phosphorylated tau in the brain.¹⁵

This is intriguing but very preliminary. Rat models of chronic stress involve extreme and sustained conditions that don’t map neatly onto a person taking Pepcid a few times a week. The drug doses, the duration, and the combination with chronic stress create a scenario far removed from typical human use. Still, the gut-brain connection is a plausible route through which chronic acid suppression could theoretically influence brain health, and it deserves further study in human populations.

Animal Evidence for Neuroprotection

Here is where the story takes an unexpected turn. While some worry that famotidine could harm the brain, a handful of recent animal studies suggest it might actually protect against Alzheimer’s-related damage. In a rat model of Alzheimer’s disease induced by aluminum chloride, famotidine-treated animals showed dose-dependent improvements in spatial memory, object recognition, and working memory. The drug appeared to inhibit acetylcholinesterase, reduce oxidative stress, lower inflammation, and decrease levels of amyloid-beta and GSK-3β, an enzyme implicated in the formation of tau tangles.¹⁶

A separate mouse study reported similar findings, with famotidine improving learning and memory in an Alzheimer’s model, likely through antioxidant and anti-inflammatory mechanisms.¹⁷ These results don’t mean famotidine is a treatment for Alzheimer’s, but they do complicate the narrative that it is straightforwardly harmful to the brain. The drug appears to have biological activities beyond simple H2 receptor blockade, and some of those activities look potentially beneficial for neurons.

A Human Trial That Improved Cognition

Perhaps the most surprising data point comes from a randomized, double-blind, placebo-controlled trial in people recovering from COVID-19 who had persistent cognitive problems. Participants who received famotidine showed significant improvement in cognitive function, as measured by standard screening tools, after six and twelve weeks of treatment compared to those taking a placebo.¹⁸

The mechanism behind this effect likely involves famotidine’s anti-inflammatory properties rather than its H2-blocking action. Post-COVID cognitive impairment is thought to involve persistent inflammation, and famotidine may help by calming that inflammatory response. This trial involved a specific population with a specific condition, so the results don’t generalize to everyone. But they do further undermine the idea that famotidine is inherently toxic to cognitive function. If anything, the drug appears to have context-dependent effects on the brain that we are only beginning to understand.

Histamine’s Complicated Role in Memory

The basic neuroscience of histamine and memory is not as simple as “more histamine equals better memory.” H2 receptor activation in the hippocampus can strengthen the connections between neurons and boost certain types of memory consolidation.¹⁹ But histamine acts through four different receptor types, each with distinct and sometimes opposing roles. Blocking H3 receptors, for instance, actually increases histamine release and has been explored as a treatment for cognitive impairment. The overall effect of any drug on this system depends on which receptors it reaches, in which brain regions, at what concentrations, and over what time frame.

Since famotidine reaches the brain poorly under normal circumstances, the theoretical risk of it disrupting hippocampal memory consolidation through H2 blockade is much smaller than you might assume from reading about what H2 receptors do in isolation. A drug that cannot reach a receptor in meaningful concentrations cannot produce a meaningful effect through that receptor, no matter how important the receptor is.

Who Should Actually Be Cautious

While the general population can likely take famotidine without worrying about dementia, certain groups deserve more careful consideration:

Older adults with delirium risk: The Beers Criteria lists famotidine as potentially inappropriate for older adults who already have or are at high risk for delirium, meaning those recovering from surgery, with infections, or with pre-existing cognitive impairment.¹²
People with significant kidney disease: Reduced clearance of famotidine means higher brain exposure. Dose adjustments are standard practice but not always followed, especially when people self-medicate with over-the-counter products.¹³
People on multiple medications: Polypharmacy increases the risk of drug interactions and cumulative side effects. Someone already taking medications with anticholinergic properties, which do have a stronger established link to cognitive decline, adds famotidine to a more complicated risk picture.

For a healthy adult taking famotidine occasionally for heartburn or even daily at standard doses, the current evidence does not support a meaningful dementia risk. The drug’s poor brain penetration, the lack of a consistent epidemiological signal, and the emerging evidence of possible neuroprotective effects all point away from the feared link. The acute cognitive side effects that show up in case reports are real but rare, reversible, and concentrated in vulnerable populations with identifiable risk factors like advanced age, IV administration, or kidney impairment.

Why Observational Studies Keep Generating Scares

It is worth understanding why studies of acid suppressants and dementia keep producing headlines, even when the evidence is this shaky. Observational pharmacoepidemiology studies are excellent at generating hypotheses but notoriously prone to a specific kind of bias. People who take medications tend to be less healthy than people who don’t. The sicker you are, the more medications you take, and the higher your baseline risk of dementia. No amount of statistical adjustment fully removes this confounding, because researchers can never measure every relevant health variable.

A large Danish study of PPIs illustrates this problem well. It found that the apparent risk of dementia associated with PPI use was strongest in the youngest age group studied and virtually disappeared in the oldest, a pattern more consistent with confounding than a true drug effect. If a drug truly caused dementia, you would generally expect the risk to increase with age and duration of use, not decrease. The authors themselves noted that unmeasured confounding was a major limitation. The same reasoning applies to observational studies of H2 blockers: the signal is weak, inconsistent across studies, and follows patterns that suggest confounding rather than causation.

Until a large, well-designed randomized trial specifically tests whether famotidine affects cognition over the long term, the observational data will remain ambiguous. Given that such a trial would require thousands of participants followed for years and would be expensive to conduct for a generic over-the-counter drug, it is unlikely to happen anytime soon. In the meantime, the totality of what we know, from pharmacology, epidemiology, animal research, and clinical trials, does not support avoiding famotidine out of fear of dementia.

1
PubMed Central. Histamine H(2) receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia
2
PubMed Central. Targeting Histamine and Histamine Receptors for Memory Regulation: An Emotional Perspective
3
PubMed Central. Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm
4
PubMed. Delirium following a switch from cimetidine to famotidine
5
PubMed. Histamine H2 blocking drugs and the risk for Alzheimer’s disease: the Rotterdam Study
6
PubMed Central. Histamine-2 Receptor Antagonist Use and Incident Dementia in an Older Cohort
7
PLOS ONE. Use of gastric acid–suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study
8
PubMed Central. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study
9
PubMed. Famotidine-associated delirium. A series of six cases.
10
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Famotidine‐Associated Mental Status Changes
11
PubMed. Famotidine-associated mental confusion in elderly patients
12
PubMed Central. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults
13
PubMed. Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes
14
PubMed. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis
15
PubMed. Impact of different gastric acid suppressants on chronic unpredictable mild stress-induced cognitive impairment in rats: A possible involvement of gut dysbiosis
16
PubMed. Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model
17
PubMed. Neuroprotective Effect of Famotidine in Mouse Models of Alzheimer’s Disease
18
PubMed Central. Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study
19
PubMed Central. Brain histamine modulates recognition memory: possible implications in major cognitive disorders